The transaction involves transfer of immovable assets, movable assets, inventory, brands and intangible assets, contracts, licenses and permissions, business records, employees along with employee benefit funds, insurance policies, other assets and assumed liabilities. While Multiples, along with its consortium partners, will acquire 100 per cent of ZAHL’s unit, the slump sale transaction is subject to closing conditions and receipt of all statutory and other approvals. It is expected to be completed within a period of 90 days.
The Multiples-led consortium, which includes Canada Pension Plan Investment Board and RARE Enterprises, has agreed to purchase the undertaking through a special purpose vehicle (SPV) called Zenex Animal Health India.
Commenting on the deal, Cadila Healthcare
Chairman Pankaj Patel said that over the last three decades, ZAHL had grown to become a pioneer and one of the market leaders in the Indian animal health industry.
“With Multiples and its consortium partners committed to growing the business, we are sure that ZAHL will continue to grow and strengthen its position in the industry.”
One of the fastest growing animal health businesses in India, ZAHL claims leadership position across a spectrum of therapeutic and nutritional products for livestock and poultry animal segments, employing roughly 700 people. It has a manufacturing facility in Haridwar. According to Arun Atrey, managing director of ZAHL, the deal is expected to be seamless for the customers, suppliers and other stakeholders, with no disruption in operations.
Multiples Alternate Asset Management Founder and Chief Executive Renuka Ramnath said the consortium will be able to invest in a business that has been helping farmers enhance their productivity and incomes. “I expect Multiples to do many such large transactions in the coming years. We are also delighted to partner CPPIB and RARE Enterprises for our first consortium deal. We look forward to working with them and helping the company unlock its full potential and create value for all stakeholders,” added Ramnath.
RARE Enterprises partner Rakesh Jhunjhunwala said the animal healthcare business segment had “huge growth potential” with the acquired firm having a top quality management team.
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.